MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
MANNKIND CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$3.09+0.05 (+1.64%)
Close on Oct 19, 2026
- Market cap
- $955.40M
- P/E (TTM)
- –
- Dividend yield
- –
MANNKIND CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenue | $251.56M | $224.65M | $216.52M | $186.36M | $181.04M | $183.12M | $178.56M | $170.27M | $158.04M | $140.56M | $126.05M | – | 63.9% | +39.0% |
| Sale of product | $148.60M | $129.07M | $114.14M | $86.79M | $84.21M | $82.54M | $82.33M | $79.47M | $77.67M | $75.23M | $74.03M | $71.27M | 37.8% | +76.5% |
| Royalties | $132.00M | $130.86M | $128.12M | $121.56M | $115.33M | $109.69M | $102.34M | $96.35M | $89.49M | $82.95M | $71.98M | $60.03M | 33.5% | +14.5% |
| Collaborations and services | $113.03M | $100.85M | $106.71M | $105.44M | $102.20M | $105.37M | $100.84M | $91.38M | $81.22M | $66.42M | $52.95M | $45.25M | 28.7% | +10.6% |
| Services | $10.07M | $5.27M | $4.33M | $5.87M | $5.37M | $4.79M | $4.61M | $578.00K | $849.00K | $1.09M | $929.00K | $1.32M | 2.6% | +87.5% |
| Product Sales | – | – | – | – | – | – | – | – | – | – | – | $115.20M | – | – |
| Manufacturing Services | – | $3.70M | $1.60M | $6.60M | $6.90M | $7.00M | $7.10M | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Mannkind's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.